A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score

A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score

Abstract Treatment response and prognosis estimation in advanced pulmonary adenocarcinoma are challenged by the significant heterogeneity of the disease. The current Response Evaluation Criteria in Solid Tumors (RECIST) criteria, despite providing a basis for solid tumor response evaluation, do not...

Full description

Bibliographic Details
Main Authors:	Xinlong Zheng, Tao Lu, Shiwen Wu, Xiaoyan Lin, Jing Bai, Xiaohui Chen, Qian Miao, Jianqun Yan, Kan Jiang, Longfeng Zhang, Xiaobing Zheng, Haibo Wang, Yiquan Xu, Weijin Xiao, Cao Li, Wenying Peng, Jianming Ding, Qiaofeng Zhong, Zihua Zou, Shanshan Yang, Yujing Li, Sihui Chen, Qiuyu Zhang, Jianfeng Yan, Guofeng Tang, Yuandong Cai, Miao kang, Tony S. K. Mok, Gen Lin
Format:	Article
Language:	English
Published:	Wiley 2024-03-01
Series:	MedComm
Subjects:	intertumoral heterogeneity intertumoral heterogeneous response lung adenocarcinoma RECIST criteria
Online Access:	https://doi.org/10.1002/mco2.493

Similar Items

Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma
by: Runzhe Chen, et al.
Published: (2022-05-01)

Intertumoral Heterogeneity of Primary Breast Tumors and Synchronous Axillary Lymph Node Metastases Reflected in IHC-Assessed Expression of Routine and Nonstandard Biomarkers
by: Wojciech Kuncman, et al.
Published: (2021-11-01)

Intertumor heterogeneity in 60 pancreatic neuroendocrine tumors associated with multiple endocrine neoplasia type 1
by: Andreas Selberherr, et al.
Published: (2019-02-01)

SETDB1 Overexpression Sets an Intertumoral Transcriptomic Divergence in Non-small Cell Lung Carcinoma
by: Yong-Kook Kang, et al.
Published: (2020-12-01)

Frequency and Prognostic Significance of Intertumoural Heterogeneity in Multifocal Jejunoileal Neuroendocrine Tumours
by: Moritz Jesinghaus, et al.
Published: (2022-08-01)

Multifocal/multicentric breast cancer: Does each focus matter?
by: Ying Tong, et al.
Published: (2023-04-01)

Angiogenic Gene Signature Derived from Subtype Specific Cell Models Segregate Proneural and Mesenchymal Glioblastoma
by: Aman Sharma, et al.
Published: (2017-07-01)

Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast Cancer
by: Shuai Li, et al.
Published: (2022-06-01)

Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma
by: Han Zou, et al.
Published: (2020-03-01)

Editorial: Spatial single-cell sequencing in studying solid cancer development
by: Behzad Mansoori, et al.
Published: (2023-12-01)

An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5
by: Tamara Lah Turnšek, et al.
Published: (2021-04-01)

Amplification of 3q26.2, 5q14.3, 8q24.3, 8q22.3, and 14q32.33 Are Possible Common Genetic Alterations in Oral Cancer Patients
by: Melvin A. Ambele, et al.
Published: (2020-04-01)

Immunohistochemical and Molecular Features of Melanomas Exhibiting Intratumor and Intertumor Histomorphologic Heterogeneity
by: Haider A. Mejbel, et al.
Published: (2019-11-01)

Evaluation of liver tumour response by imagingKey points
by: Jules Gregory, et al.
Published: (2020-06-01)

Are radiologists ready to evaluate true response to immunotherapy?
by: Inci Kizildag Yirgin, et al.
Published: (2021-02-01)

Tumor Response Evaluation Using iRECIST: Feasibility and Reliability of Manual Versus Software-Assisted Assessments
by: Inka Ristow, et al.
Published: (2024-02-01)

Tumor response assessment on imaging following immunotherapy
by: Antonia M. Berz, et al.
Published: (2022-10-01)

Erratum: Tumor response assessment on imaging following immunotherapy
by: Frontiers Production Office
Published: (2023-03-01)

Tumor Response Criteria in Oncoimaging: RECIST Criteria and beyond—Part 2
by: Akshay D. Baheti, et al.
Published: (2019-08-01)

Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience
by: Caroline Touloupas, et al.
Published: (2021-10-01)

Imaging biomarkers for evaluating tumor response: RECIST and beyond
by: Ching-Chung Ko, et al.
Published: (2021-07-01)

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives
by: Vivek Subbiah, et al.
Published: (2017-02-01)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
by: Hyo Jung Park, et al.
Published: (2021-01-01)

Response Assessment of Treated Hepatocellular Carcinoma
by: Amitkumar J. Choudhari, et al.
Published: (2023-09-01)

Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma Model
by: Shuyang S. Qin, et al.
Published: (2021-05-01)

Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group – ESOI Joint Paper
by: Laure Fournier, et al.
Published: (2022-01-01)

Incorporating lesion-to-lesion heterogeneity into early oncology decision making
by: Rukmini Kumar, et al.
Published: (2023-06-01)

Elevated tumor markers for monitoring tumor response to immunotherapy
by: Yi Yang, et al.
Published: (2022-04-01)

BUSCANDO UNA CURVA GENERAL DE RESPUESTA A LA QUIMIOTERAPIA BASADA EN LA EVALUACIÓN RADIOLÓGICA CON CRITERIO RECIST
by: Mauricio Canals L, et al.

Development of an algorithm for evaluating the impact of measurement variability on response categorization in oncology trials
by: Jeong-Hwa Yoon, et al.
Published: (2019-05-01)

Imaging response assessment for oncology: An algorithmic approach
by: Kathleen Ruchalski, et al.
Published: (2022-01-01)

Predicting the radiotherapeutic treatment response of non-small cell lung cancer
by: Soumyajit Das, et al.
Published: (2022-01-01)

Response Evaluation after Neoadjuvant Chemotherapy for Resectable Gastric Cancer
by: Alina Desiree Sandø, et al.
Published: (2023-04-01)

Computed Tomography and Spirometry Can Predict Unresectability in Malignant Pleural Mesothelioma
by: Alice Bellini, et al.
Published: (2021-09-01)

Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients
by: Thomas Bartl, et al.
Published: (2021-11-01)

Role of multislice computed tomography 3D volumetric analysis in the assessment of the therapeutic response of hepatocellular carcinoma after transarterial chemoembolization
by: Mohamed Fouad Osman, et al.
Published: (2021-07-01)

Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation
by: N. N. Babyshkina, et al.
Published: (2022-11-01)

Diffusion-weighted MR imaging diagnostic merits in the post-therapeutic assessment of musculoskeletal soft tissue sarcoma
by: Amr Farouk Ibrahim Moustafa, et al.
Published: (2019-11-01)

RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?
by: Antoine Iannessi, et al.
Published: (2021-03-01)

Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy
by: Cory Pierson, et al.
Published: (2018-02-01)